Clinical Trials Browser

Interventional × venetoclax × Thoracic × Clear all

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04422210 2021-11-08

A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

Phase 1 Terminated

2 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04543916 2021-03-03

Venetoclax and Irinotecan in Relapsed/Refractory SCLC

Phase 1/2 Withdrawn

Thoracic

Small Cell Lung Carcinoma

NCT04274907 2021-02-11

A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Phase 1 Terminated

2 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02391480 2019-11-29

A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer

Phase 1 Completed

128 enrolled

BreastGenitourinaryLymphoidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Prostatic Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma

Clinical Trials

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

Venetoclax and Irinotecan in Relapsed/Refractory SCLC

A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer